Chronic back pain with possible prescription opioid misuse

JAMA

Volumn 309, Issue 9, 2013, Pages 919-925

  Alford, Daniel P ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ATORVASTATIN; BENZODIAZEPINE; ESOMEPRAZOLE; FLUTICASONE; GABAPENTIN; HYDROCHLOROTHIAZIDE; IPRATROPIUM BROMIDE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PERCOCET; PLACEBO; SALBUTAMOL; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALGESIA; ANXIETY DISORDER; BACKACHE; CENTRAL SLEEP APNEA SYNDROME; CHRONIC BACK PAIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; HYPERALGESIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; LOW BACK PAIN; LOW DRUG DOSE; LUMBAR DISK HERNIA; NAUSEA; OPIATE ADDICTION; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCIATIC NERVE INJURY; SEDATION; SIDE EFFECT; SLEEP DISORDERED BREATHING; SPINE SURGERY; SYSTEMATIC REVIEW (TOPIC); URINALYSIS; WITHDRAWAL SYNDROME; CHRONIC DISEASE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; INFORMED CONSENT; PATIENT COMPLIANCE; PHYSIOLOGIC MONITORING; URINE;

ANALGESICS, OPIOID; BACK PAIN; CHRONIC DISEASE; HUMANS; INFORMED CONSENT; MEDICATION ADHERENCE; MONITORING, PHYSIOLOGIC; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; URINALYSIS;

MLCS; MLOWN;

EID: 84874739418     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.522     Document Type: Review

References (69)

1. Simon LS. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research. Vol 26. Washington, DC: National Academies Press; 2012.
2. Breuer B, Pappagallo M, Tai JY, Portenoy RK. US board-certified pain physician practices: uniformity and census data of their locations. J Pain. 2007;8(3):244-250.
3. Breuer B, Cruciani R, Portenoy RK. Pain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national survey. South Med J. 2010;103(8):738-747.
4. Yanni LM, McKinney-Ketchum JL, Harrington SB, et al. Preparation, confidence, and attitudes about chronic noncancer pain in graduate medical education. J Grad Med Educ. 2010;2(2):260-268.
5. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652-655.
6. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.
7. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171-186.
8. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225-235.
9. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
10. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) 1998-2008. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Dept of Health and Human Services; 2010. DASIS Series: S-50, HHS publication (SMA) 09-4471.
11. Substance Abuse and Mental Health Services Administration. Results from the 2010 national survey on drug use and health: Summary of national findings. Rockville, MD: US Dept of Health and Human Services; 2011. NSDUH series H-41, publication (SMA) 11-4658.
12. McCleane G, Smith HS. Opioids for persistent noncancer pain. Med Clin North Am. 2007;91(2):177-197.
13. Tremblay J, Hamet P. Genetics of pain, opioids, and opioid responsiveness. Metabolism. 2010;59(suppl 1):S5-S8.
14. Smith HS. Variations in opioid responsiveness. Pain Physician. 2008;11(2):237-248.
15. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.
16. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116-127.
17. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2)(suppl):S105-S120.
18. Panagiotou I, Mystakidou K. Non-analgesic effects of opioids: opioids' effects on sleep (including sleep apnea). Curr Pharm Des. 2012;18(37):6025-6633.
19. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170-175.
20. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25(4):310-315.
21. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91(2):199-211.
22. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490-518.
23. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
24. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010;170(16):1425-1432.
25. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.
26. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-691.
27. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129(3):235-255.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
29. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26(1):655-667.
30. Weissman DE, Haddox JD. Opioid pseudoaddiction - an iatrogenic syndrome. Pain. 1989;36(3):363-366.
31. Isaacson JH, Hopper JA, Alford DP, Parran T. Prescription drug use and abuse: risk factors, red flags, and prevention strategies. Postgrad Med. 2005;118(1):19-26.
32. Executive Office of the President, Office of National Drug Control Policy. Pulse Check: Trends in Drug Abuse, January 2004. http://infousa.state. gov/government/branches/docs/pulse-check.pdf. Accessed February 8, 2013.
33. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain. 2006;22(2):173-181.
34. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
35. Model policy for the use of controlled substances for the treatment of pain. http://www.fsmb.org/pain-model-policy.html. Accessed January 16, 2013.
36. Chou R, Fanciullo GJ, Fine PG, et al American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
37. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP). J Pain Symptom Manage. 2006;32(3):287-293.
38. Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain. 2010;11(11):1047-1055.
39. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.
40. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28(3):250-258.
41. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173-179.
42. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131-146.
43. Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med. 2008;9:S145-S166.
44. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
45. Nicolaidis C. Police officer, deal-maker, or health care provider? moving to a patient-centered framework for chronic opioid management. Pain Med. 2011;12(6):890-897.
46. Fishman SM, Kreis PG. The opioid contract. Clin J Pain. 2002;18(4)(suppl):S70-S75.
47. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med. 2006;119(4):292-296.
48. Reisfield GM, Goldberger BA, Bertholf RL. "False-positive" and "false-negative" test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952.
49. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84(7):593-601.
50. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712-720.
51. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11(2)(suppl):S5-S62.
52. Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683-694.
53. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.
54. Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425.
55. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13(2):160-164.
56. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324-1334.
57. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133-137.
58. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733-738.
59. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573-582.
60. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15(3):184-191.
61. Pesce A, West C, Rosenthal M, et al. Illicit drug use in the pain patient population decreases with continued drug testing. Pain Physician. 2011;14(2):189-193.
62. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123-129.
63. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11(2)(suppl):S155-S180.
64. Reisfield GM, Webb FJ, Bertholf RL, Sloan PA, Wilson GR. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag. 2007;3(6):333-337.
65. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260-267.
66. Perrone J, Nelson LS. Medication reconciliation for controlled substances - an "ideal" prescription-drug monitoring program. N Engl J Med. 2012;366(25):2341-2343.
67. Evers GC. Pseudo-opioid-resistant pain. Support Care Cancer. 1997;5(6):457-460.
68. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137(8):688-692.
69. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379-384.